You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 8,735,359


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,735,359
Title:Combinations of modalities for the treatment of diabetes
Abstract: A method of treating, preventing, or delaying the progression of Type 1 diabetes mellitus by administering an effective amount of a fusion protein composition comprising a T-cell co-stimulation antagonist and a portion of an immunoglobulin molecule and an effective amount of a Type 1 diabetes autoantigen. The method includes, for example, administering a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) molecule and a Type 1 diabetes autoantigen. Pharmaceutical compositions are also provided herewith.
Inventor(s): Orban; Tihamer (Brookline, MA)
Assignee: Orban Biotech LLC (Brookline, MA)
Application Number:13/534,571
Patent Claims:1. A method of treating diabetes mellitus in a subject comprising administering to the subject: a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) fusion protein in a pharmaceutically acceptable carrier, and preproinsulin in a pharmaceutically acceptable carrier.

2. The method of claim 1, wherein said CTLA4 fusion protein is abatacept.

3. The method of claim 1, wherein said preproinsulin comprises amino acids 33-47 of SEQ ID NO:1.

4. The method of claim 1, wherein said pharmaceutically acceptable carrier is an oil-based carrier.

5. The method of claim 4, wherein said oil-based carrier is IFA or Montanide ISA.

Details for Patent 8,735,359

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Bristol-myers Squibb Company ORENCIA abatacept For Injection 125118 12/23/2005 ⤷  Try a Trial 2039-03-29
Bristol-myers Squibb Company ORENCIA abatacept Injection 125118 07/29/2011 ⤷  Try a Trial 2039-03-29
Bristol-myers Squibb Company ORENCIA abatacept Injection 125118 06/07/2016 ⤷  Try a Trial 2039-03-29
Bristol-myers Squibb Company ORENCIA abatacept Injection 125118 03/30/2017 ⤷  Try a Trial 2039-03-29
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.